Table 2 Patient characteristics during the 48 hours following randomization
Variables | Continuous control of Pcuffn = 64 | Routine care n = 64 | p | Continuous control of Pcuffn = 64 | p | Routine care n = 64 | p | ||
|---|---|---|---|---|---|---|---|---|---|
Tapered cuff n = 32 | Cylindrical cuff n = 32 | Tapered cuff n = 32 | Cylindrical cuff n = 32 | ||||||
Quantity of enteral nutrition, ml/day | 1000 | 1000 | 0.433 | 1000 | 1000 | 0.960 | 1000 | 1000 | 0.241 |
(500–1000) | (500–1500) | (500–1000) | (500–1000) | (500–1000) | (500–1500) | ||||
Gastric residual volume, ml | 0 (0–20) | 0 (0–20) | 0.871 | 0 (0–15) | 0 (0–27) | 0.726 | 0 (0–60) | 0 (0–5) | 0.294 |
Sedation | 28 (43) | 29 (45) | > 0.999 | 14 (43) | 14 (43) | >0.999 | 15 (46) | 14 (43) | >0.999 |
Ramsay score | 2 (2–3) | 2 (2–3) | 0.641 | 2 (2–3) | 2 (2–3) | 0.718 | 2 (2–3) | 2 (2–3) | 0.729 |
Neuromuscular blocking agent use | 6 (9) | 7 (10) | > 0.999 | 3 (9) | 3 (9) | >0.999 | 3 (9) | 4 (12) | >0.999 |
Glasgow coma score | 14 (10–15) | 15 (10–15) | 0.310 | 13 (10–15) | 14 (8–15) | 0.738 | 14 (10–15) | 15 (8–15) | 0.908 |
PEEP | 6 (5–8) | 6 (5–9) | 0.943 | 6 (5–8) | 7 (5–9) | 0.234 | 6 (5–9) | 7 (5–9) | 0.166 |
Ventilatory mode | 0.329 | 0.885 | 0.433 | ||||||
ACV | 36 (56) | 37 (57) | 18 (56) | 18 (56) | 21 (65) | 16 (50) | |||
PSV | 23 (35) | 25 (39) | 11 (34) | 12 (37) | 10 (31) | 15 (46) | |||
BPPV | 5 (7) | 2 (3) | 3 (9) | 2 (6) | 1 (3) | 1 (3) | |||
Stress ulcer prophylaxis or treatment | >0.999 | 0.688 | 0.109 | ||||||
Sucralfate | 32 (50) | 32 (50) | 15 (46) | 17 (53) | 13 (40) | 19 (59) | |||
Proton pump inhibitors | 25 (39) | 25 (39) | 13 (40) | 12 (37) | 13 (40) | 12 (37) | |||
Prokinetic drugs | 12 (18) | 12 (18) | > 0.999 | 6 (18) | 6 (18) | >0.999 | 7 (21) | 5 (15) | 0.749 |
Vomiting | 3 (4) | 1 (1) | 0.625 | 0 | 3 (9) | 0.237 | 1 (3) | 0 | >0.999 |
Head-of-bed position | 40 (35–40) | 40 (35–40) | 0.846 | 40 (35–45) | 40 (35–40) | 0.602 | 40 (35–40) | 40 (35–45) | 0.244 |